These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21540216)

  • 1. Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy.
    Sun HY; Fujitani S; Quintiliani R; Yu VL
    Chest; 2011 May; 139(5):1172-1185. PubMed ID: 21540216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia.
    Fish DN; Kiser TH
    Pharmacotherapy; 2013 Oct; 33(10):1022-34. PubMed ID: 23744833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should antibiotic combinations be used to treat ventilator-associated pneumonia?
    Eggimann P; Revelly JP
    Semin Respir Crit Care Med; 2006 Feb; 27(1):68-81. PubMed ID: 16508883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies.
    El Zowalaty ME; Al Thani AA; Webster TJ; El Zowalaty AE; Schweizer HP; Nasrallah GK; Marei HE; Ashour HM
    Future Microbiol; 2015; 10(10):1683-706. PubMed ID: 26439366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.
    Aoki N; Tateda K; Kikuchi Y; Kimura S; Miyazaki C; Ishii Y; Tanabe Y; Gejyo F; Yamaguchi K
    J Antimicrob Chemother; 2009 Mar; 63(3):534-42. PubMed ID: 19147523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
    Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin.
    Hamer DH
    Am J Respir Crit Care Med; 2000 Jul; 162(1):328-30. PubMed ID: 10903263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
    Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
    Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams.
    Ribera A; Benavent E; Lora-Tamayo J; Tubau F; Pedrero S; Cabo X; Ariza J; Murillo O
    J Antimicrob Chemother; 2015 Dec; 70(12):3357-65. PubMed ID: 26419763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the treatment of Pseudomonas aeruginosa pneumonia.
    El Solh AA; Alhajhusain A
    J Antimicrob Chemother; 2009 Aug; 64(2):229-38. PubMed ID: 19520717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum.
    Traugott KA; Echevarria K; Maxwell P; Green K; Lewis JS
    Pharmacotherapy; 2011 Jun; 31(6):598-608. PubMed ID: 21923444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
    Ciofu O; Giwercman B; Pedersen SS; Høiby N
    APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
    Lodise TP; Miller CD; Graves J; Furuno JP; McGregor JC; Lomaestro B; Graffunder E; McNutt LA
    Antimicrob Agents Chemother; 2007 Feb; 51(2):417-22. PubMed ID: 17158943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of antibiotics in biofilm infections of Pseudomonas aeruginosa in vitro and in vivo.
    Hengzhuang W; Høiby N; Ciofu O
    Methods Mol Biol; 2014; 1147():239-54. PubMed ID: 24664838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
    Kwa AL; Loh C; Low JG; Kurup A; Tam VH
    Clin Infect Dis; 2005 Sep; 41(5):754-7. PubMed ID: 16080101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.
    Obritsch MD; Fish DN; MacLaren R; Jung R
    Pharmacotherapy; 2005 Oct; 25(10):1353-64. PubMed ID: 16185180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A peptide based on homologous sequences of the β-barrel assembly machinery component BamD potentiates antibiotic susceptibility of Pseudomonas aeruginosa.
    Mori N; Ishii Y; Tateda K; Kimura S; Kouyama Y; Inoko H; Mitsunaga S; Yamaguchi K; Yoshihara E
    J Antimicrob Chemother; 2012 Sep; 67(9):2173-81. PubMed ID: 22628248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antipyocyanic antibiotic therapy. Principles and efficacy factors].
    Cohen R
    Arch Pediatr; 2006 Oct; 13 Suppl 1():S10-2. PubMed ID: 17370390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.
    Zavascki AP; Carvalhaes CG; Picão RC; Gales AC
    Expert Rev Anti Infect Ther; 2010 Jan; 8(1):71-93. PubMed ID: 20014903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.